These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30272286)

  • 21. Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair.
    Moschetta-Pinheiro MG; Colombo J; de Souza Tuckumantel M; Rebolho GK; de Campos Zuccari DAP
    Anticancer Agents Med Chem; 2022; 22(10):2036-2045. PubMed ID: 34629045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.
    Corrales-Sánchez V; Noblejas-López MDM; Nieto-Jiménez C; Pérez-Peña J; Montero JC; Burgos M; Galán-Moya EM; Pandiella A; Ocaña A
    J Cell Mol Med; 2020 Mar; 24(5):3117-3127. PubMed ID: 32032474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
    Karginova O; Siegel MB; Van Swearingen AE; Deal AM; Adamo B; Sambade MJ; Bazyar S; Nikolaishvili-Feinberg N; Bash R; O'Neal S; Sandison K; Parker JS; Santos C; Darr D; Zamboni W; Lee YZ; Miller CR; Anders CK
    Mol Cancer Ther; 2015 Apr; 14(4):920-30. PubMed ID: 25824335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
    Moens S; Zhao P; Baietti MF; Marinelli O; Van Haver D; Impens F; Floris G; Marangoni E; Neven P; Annibali D; Sablina AA; Amant F
    Sci Rep; 2021 Feb; 11(1):3176. PubMed ID: 33542435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 26. Anticancer effects of methotrexate in combination with α‑tocopherol and α‑tocopherol succinate on triple‑negative breast cancer.
    Wei CW; Yu YL; Chen YH; Hung YT; Yiang GT
    Oncol Rep; 2019 Mar; 41(3):2060-2066. PubMed ID: 30628707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
    Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
    Kala R; Shah HN; Martin SL; Tollefsbol TO
    BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
    Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
    Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
    Liang DH; Choi DS; Ensor JE; Kaipparettu BA; Bass BL; Chang JC
    Cancer Lett; 2016 Jul; 376(2):249-58. PubMed ID: 27060208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
    Mazzucchelli S; Truffi M; Baccarini F; Beretta M; Sorrentino L; Bellini M; Rizzuto MA; Ottria R; Ravelli A; Ciuffreda P; Prosperi D; Corsi F
    Sci Rep; 2017 Aug; 7(1):7505. PubMed ID: 28790402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
    Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
    Teo ZL; Versaci S; Dushyanthen S; Caramia F; Savas P; Mintoff CP; Zethoven M; Virassamy B; Luen SJ; McArthur GA; Phillips WA; Darcy PK; Loi S
    Cancer Res; 2017 Nov; 77(22):6340-6352. PubMed ID: 28947417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
    Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells.
    Mani C; Tripathi K; Omy TR; Reedy M; Manne U; Palle K
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166300. PubMed ID: 34748904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab‑paclitaxel on triple‑negative and luminal A breast cancer cells.
    Topçul M; Çeti N İL; Özbaş Turan S; Kolusayin Ozar MÖ
    Oncol Rep; 2018 Jul; 40(1):527-535. PubMed ID: 29658592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.